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1078–5Large abdominal aortic aneurysms (AAAs) are associated with coagulation abnormalities, which are significantly reduced
by low molecular weight heparin (LMWH). Considering anti-inflammatory properties of heparin we verified, whether
LMWH influences MMP-2/-9 in AAA patients. The study involved 26 AAA individuals, 10 patients with coagulation
abnormalities received LMWH and 16 were a control group. The plasma activity of MMP-2/-9 was measured using
zymography. We found that, in addition to the reduction of coagulation abnormalities, LMWH treatment was associated
with the decreased MMP-9 but not MMP-2 activity. Therefore, LMWH use could be considered as a valuable pretreatment
before an elective aneurysm repair.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The abdominal aortic aneurysm (AAA) development
results from chronic destruction of the aortic wall, me-
diated by extracellular matrix metalloproteinases
(MMPs), mainly MMP-9.1 The increased MMPs activ-
ity in the damaged aortic wall correlates with an in-
creased risk of aneurysm rupture. Therefore, it is
possible that introduction of MMPs inhibitors to the
clinical practice would decrease the aneurysm rupture
frequency. Indeed, such a therapeutic approach is cur-
rently under extensive investigation.2 It seems to be
especially useful in individuals with small AAA, to
decrease the aneurysm dilatation rate. This approach
would also be beneficial for patients with large AAA
to prevent its rupture until an elective repair. Numer-
ous agents have been analyzed establishing their
capability of MMPs inhibition. However, their effec-
tiveness, especially in context of possible adverse
events, remains controversial.3sponding author. T. Grzela, MD, PhD, Department of Histol-
d Embryology, Biostructure Research Center at the Warsaw
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884/000159+ 03 $34.00/0  2007 European Society for VasculaRecently,wehavedemonstrated that large aneurysms
are usually associated with subclinical coagulation
abnormalities, that could be successfully treated with
low doses of low molecular weight heparin (LMWH).4
Since heparin, in addition to anti-coagulant activity, dis-
plays someanti-inflammatoryproperties,5we attempted
to verify whether short-term LMWH treatment could
influence MMP-2 and/or MMP-9 plasma activity in
AAA patients.Report
The study involved 26 AAA individuals qualified for
an elective aneurysm repair, after exclusion of any
concomitant diseases, which could independently
provoke haemostatic abnormalities (malignancy,
diabetes, hepatic cirrhosis, rheumatoid arthritis, renal
insufficiency). On the basis of an extended laboratory
screening for subclinical blood coagulation abnormal-
ities, patients were divided into two subgroups, as
described previously.4 The analyzed parameters in-
cluded D-dimer (with threshold level >3000 ng/ml)
and prothrombin fragment PF1þ2 (>2 nM) concentra-
tion and activation of fibrinolysis (>20%) (Table 1).r Surgery. Published by Elsevier Ltd. All rights reserved.
Table 1. Clinical data
Patient’ parameters Control AAA
patients
(n¼ 16)
LMWH-treated
group
(n¼ 10)
Age 65.5 7.9 70.1 6.5
Sex (male/female) 15/1 9/1
AAA diameter (mm) 53.8 8.2 69.7 12.0*
Laboratory test No LMWH Before
LMWH
After
LMWH
Blood platelets
( 103/ml)
225 38 192 38 233 42
Activated partial
tromboplastin time (s)
36.4 2.5 36.2 2.3 37.2 3.9
Prothrombin time (s) 15.3 1.1 15.8 0.8 15.2 0.9
Fibrinogen (mg/dl) 403 76 384 42 454 75**
D-dimer (ng/ml) 776 330 5260 2120* 3018 1044**
Prothrombin fragment
1þ 2 (nM)
1.15 0.32 4.13 1.55* 1.91 0.75**
Fibrinolysis activation
in the plasma (%)
4 5 58 36* 23 31**
* statistically significantly different from AAA control group.
** statistically significantly different from group before LMWH
treatment.
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of nadroparinum calcium, s.c., twice daily) injection
for 5-7 days,4 whereas the second group (n¼ 16)
was a control group. All patients gave their writtenFig. 1. MMP-9 zymograms of AAA control group (panel A) an
sents one individual’s plasma sample, displaying MMP-9-spe
MMP-9 amount/activity. Each rectangle in panel B contains a
before and after LMWH treatment, respectively. The calcula
Squares represent patients from AAA control group, whereas c
and after treatment (filled circles). In each group mean valu
represented by dotted lines. NS e non significant.
Eur J Vasc Endovasc Surg Vol 35, February 2008informed consent to participate in the study that
was approved by the local ethics committee.
Blood morphology and selected haemostatic
parameters were measured as described previously.4
The changes in coagulation tests observed in
LMWH-treated AAA patients were shown in Table 1.
Plasma activity of MMP-2 and MMP-9 was mea-
sured using standard zymography. Quantitative anal-
ysis of zymograms was performed using digital gel
documentation system GDS (UVP, Cambridge, UK).
The conversion of sample activity to the specific
MMP concentration (ng/ml) was done by a compari-
son of sample in-gel gelatinolytic activity to the activ-
ity curve of respective recombinant MMP, used in
serial dilutions, at known concentrations.
We found that individuals with subclinical coagu-
lation abnormalities displayed mean MMP-9 plasma
activity significantly higher, than AAA individuals
with normal coagulation parameters (p< 0.01, by
Mann-Whitney U-test) (Fig. 1). Interestingly, after
5-7 days of LMWH administration we observed a sta-
tistically significant ( p< 0.003, by matched pair T-test)
decrease in MMP-9 plasma activity (Fig. 1). The mean
MMP-9 activity in LMWH-treated patients reachedd LMWH-treated AAA patients (panel B). Each band repre-
cific activity, with the band thickness corresponding to the
pair of MMP-9 bands from one individual’ plasma samples,
ted MMP-9 concentration (ng/ml) was shown in panel C.
ircles represent LMWH-treated patients before (open circles)
es have been shown as solid lines and median values are
161LMWH Decreases MMP-9 Activity in AAA Patientsthe level of that of the control group. In contrast to
MMP-9, no difference in MMP-2 plasma activity
between both groups, or any influence of LMWH
administration on the MMP-2 activity has been
observed (not shown).Discussion
It has been demonstrated that large aneurysms usu-
ally correlate with subclinical or clinically overt coag-
ulation abnormalities and require preoperative
LMWH treatment.4 On the other hand, the aneurysm
diameter and rupture risk directly correlate with
MMP-9 level.1 However, the relationship between
AAA-related coagulation abnormalities and high
levels of MMP-9 remains uncertain. Moreover, it is
unclear, what is a chronology of events. Two hypoth-
eses are to be taken under consideration. The first pos-
sible mechanism is the primary hyperactivity of
MMP-9 leading to the development of abdominal an-
eurysm and consequently intravascular coagulation in
the aneurysmal sack. This hypothesis could be sup-
ported by the observation of high MMP-9 levels in in-
dividuals with small AAA without coagulation
abnormalities. The second proposed hypothesis is
somehow the evolution of the first and includes two
steps. Primary mild increase of MMP-9 activity results
in AAA development and intraaneurysmal clotting
formation. However, intravascular coagulation in the
aneurysmal sack could lead to the further increase
of MMP-9. This theory could be supported by the
fact that LMWH treatment reduced coagulation
abnormalities and was associated with the decrease
of MMP-9 activity. The observed LMWH-dependent
decrease of MMP-9 activity is probably indirect, since,
in our in vitro studies LMWH had an effect on neither
MMP-9 activity, nor on MMP-9 production by leuko-
cytes (data not shown).Thus, the use of LMWH, especially in large aneu-
rysms, would offer an attractive approach with double
benefit. Indeed, in our observation the LMWH
treatment resulted in advantageous effect on the
coagulation abnormalities 4 and attenuation of MMP-
9 hyperactivity. Therefore, LMWHuse could be consid-
ered as a valuable pretreatment before an elective
aneurysm repair. However, the effect of LMWH on
MMP-9activity in individualswith smallAAAremains
to be analyzed.Acknowledgements
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